Ken Griffin Adma Biologics, Inc. Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 121,400 shares of ADMA stock, worth $2.39 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

121,400

Previous 23,800 410.08%

Holding current value

$2.39 Million

Previous $157,000 764.33%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$5.98 - $11.18 $1.58 Million - $2.96 Million	-264,338 Reduced 89.7%	30,351 $339,000
Q1 2024 May 15, 2024	BUY	$4.4 - $6.74 $263,696 - $403,934	59,931 Added 25.53%	294,689 $1.94 Million
Q4 2023 Feb 14, 2024	SELL	$3.08 - $4.52 $1.95 Million - $2.86 Million	-632,585 Reduced 72.93%	234,758 $1.06 Million
Q3 2023 Nov 14, 2023	BUY	$3.47 - $4.61 $2.82 Million - $3.74 Million	812,084 Added 1469.6%	867,343 $3.11 Million
Q2 2023 Aug 14, 2023	SELL	$3.12 - $4.22 $584,803 - $790,984	-187,437 Reduced 77.23%	55,259 $203,000
Q1 2023 May 15, 2023	BUY	$3.01 - $3.87 $271,128 - $348,594	90,076 Added 59.02%	242,696 $803,000
Q4 2022 Feb 14, 2023	SELL	$2.47 - $3.88 $519,038 - $815,331	-210,137 Reduced 57.93%	152,620 $592,000
Q3 2022 Nov 14, 2022	BUY	$2.03 - $2.86 $409,105 - $576,375	201,530 Added 125.0%	362,757 $882,000
Q2 2022 Aug 15, 2022	SELL	$1.43 - $2.2 $109,279 - $168,121	-76,419 Reduced 32.16%	161,227 $319,000
Q1 2022 May 16, 2022	SELL	$1.28 - $1.83 $487,171 - $696,503	-380,603 Reduced 61.56%	237,646 $435,000
Q4 2021 Feb 14, 2022	BUY	$1.09 - $1.66 $503,428 - $766,689	461,861 Added 295.33%	618,249 $871,000
Q3 2021 Nov 15, 2021	BUY	$1.13 - $1.65 $32,061 - $46,815	28,373 Added 22.16%	156,388 $177,000
Q2 2021 Aug 16, 2021	SELL	$1.51 - $2.07 $139,594 - $191,365	-92,447 Reduced 41.93%	128,015 $204,000
Q1 2021 May 17, 2021	BUY	$1.67 - $2.95 $116,370 - $205,564	69,683 Added 46.22%	220,462 $388,000
Q4 2020 Feb 16, 2021	BUY	$1.8 - $2.56 $10,281 - $14,622	5,712 Added 3.94%	150,779 $294,000
Q2 2020 Aug 14, 2020	BUY	$2.42 - $3.29 $257,942 - $350,674	106,588 Added 277.0%	145,067 $425,000
Q1 2020 May 15, 2020	SELL	$1.5 - $4.59 $5,142 - $15,734	-3,428 Reduced 8.18%	38,479 $111,000
Q4 2019 Feb 14, 2020	SELL	$3.89 - $5.15 $26,856 - $35,555	-6,904 Reduced 14.14%	41,907 $168,000
Q3 2019 Nov 14, 2019	BUY	$3.19 - $5.39 $84,930 - $143,503	26,624 Added 120.0%	48,811 $217,000
Q2 2019 Aug 14, 2019	BUY	$3.52 - $5.24 $32,725 - $48,716	9,297 Added 72.13%	22,187 $86,000
Q1 2018 May 11, 2018	BUY	$3.21 - $5.21 $41,376 - $67,156	12,890 New	12,890 $59,000

Others Institutions Holding ADMA

# of Institutions

295

Shares Held

180M

Call Options Held

535K

Put Options Held

21.2K

View Full List

About ADMA BIOLOGICS, INC.

Ticker ADMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 196,356,992
Market Cap $3.86B
Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...

More about ADMA

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account